Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Calin R, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V
2013 J. Clin. Virol. Volume 58 Issue 2
PubMed 23958588 DOI 10.1016/j.jcv.2013.07.018
BACKGROUND
Due to common routes of transmission, HIV and HBV are frequently found as concomitant infections. The dynamic of liver disease in co-infected patients is important to understand for appropriate clinical management. Conflicting data surround the role played by genotype-G HBV (HBV-G) during the course of HIV co-infection.
OBJECTIVES
This study aims to assess, using non-invasive methods, liver disease progression in HIV-HBV genotype-G co-infected patients.
STUDY DESIGN
Co-infected patients with residual HBV replication (n=125) were screened for HBV-G infection by specific real-time PCR. The impact of HBV-G on liver fibrosis progression, as assessed by a non invasive biomarker (Fibrotest), was evaluated first, by a cross sectional analysis comparing fibrosis between HBV-G (n=23) and non-G (n=55) infected patients and second, by a longitudinal study performed over a 5 year period.
RESULTS
Selected patients were mostly male (90%), with homogenous characteristics between the HBV-G and non-G infected groups, in terms of age, known duration of HIV disease, immune and virological status and duration of HIV/HBV treatment. HBV-G infected patients were exclusively from Western Europe with homosexual intercourses (83%) as principal risk of transmission. Cross sectional analysis revealed comparable liver disease severity distribution between HBV-G and non-G infected patients. Co-infection with other hepatitis viruses and low CD4-nadir, but not HBV-G co-infection, were associated with a 5-year risk of fibrosis progression.
CONCLUSIONS
This study suggests that HBV-G infection is not significantly associated with a more severe liver disease and does not have a deleterious impact on fibrosis progression in efficiently treated HIV-HBV co-infected patients.
Citation Reference: